A carregar...
HCV Replicon Systems: Workhorses of Drug Discovery and Resistance
The development of direct-acting antivirals (DAAs) has revolutionized the state-of-the art treatment of HCV infections, with sustained virologic response rates above 90%. However, viral variants harboring substitutions referred to as resistance-associated substitutions (RASs) may be present in basel...
Na minha lista:
| Publicado no: | Front Cell Infect Microbiol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7344236/ https://ncbi.nlm.nih.gov/pubmed/32714881 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcimb.2020.00325 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|